Using a GLP-1 medicine to ease side effects of lorlatinib for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether a GLP-1 medicine (like Ozempic) can reduce the side effects of lorlatinib, a drug used to treat a certain type of lung cancer. If you are already taking lorlatinib, this trial may help you manage treatment-related problems like weight loss or appetite changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are already taking lorlatinib as your first treatment for advanced ALK-positive lung cancer.
- Your cancer has not been treated with any other therapy first (first-line treatment).
- You are not allergic to GLP-1 medicines (like semaglutide).
- You do not have active mental health issues that are unstable or current thoughts of suicide.
- You do not have severe organ failure or serious illness.
- You do not have a history of anorexia nervosa or pancreatitis.
- You or your family have never had medullary thyroid cancer or MEN2 syndrome.
- You have not used a GLP-1 medication or other weight-loss drug in the last 30-90 days.
- You are not pregnant, breastfeeding, or planning pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two ways to manage weight: taking a GLP-1 medication (like tirzepatide or semaglutide) versus making lifestyle changes without medication. It will help researchers learn which approach works best for people with overweight or obesity.
This study tests a new injectable medication called cagrilintide for people with obesity who had to stop GLP-1 drugs (like Ozempic or Wegovy) because of stomach problems. The goal is to see if cagrilintide causes fewer stomach side effects while still helping with weight.
This study compares how a GLP-1 medication (a drug that helps control blood sugar and weight) changes the way your body stores and uses fat. Researchers will use imaging scans to see these changes over time in people with metabolic syndrome—a cluster of health conditions including high blood pressure, high cholesterol, and excess weight.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
This study teaches adults on GLP-1 medication (like Ozempic or Wegovy) how to eat better and lose weight using a smartphone app. Researchers want to see if personalized nutrition advice helps you get better results from your medication.
This study tests an experimental medicine (LAE102) combined with a known weight-loss drug (tirzepatide) to see if it helps people with obesity lose more weight safely. You would receive the study drug or a placebo (a dummy shot), and the goal is to find a better way to manage weight.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.